


Survival for older patients with acute myeloid leukemia: a population-based study

Betul Oran^{1,2} and Daniel J. Weisdorf^{1,2}

¹University of Minnesota Hematology, Oncology and Transplantation; and ²Department of Medicine, Minneapolis, Minnesota, USA

Citation: Oran B, and Weisdorf DJ. Survival for older patients with acute myeloid leukemia: a population-based study. *Haematologica* 2012;97(12):1916-1924. doi:10.3324/haematol.2012.066100

Online Supplementary Figure S1. Selection of study cohort.



AML: acute myeloid leukemia; HMO: health maintenance organization.

Online Supplementary Table S1. Codes to capture covariates related with diagnosis, procedures and treatments in the study cohort.

Category	Source and Type	Codes
AML histology	SEER PEDFS histology ICD-03	9840, 9861, 9865-9867, 9869-9874, 9891, 9895-9897, 9910, 9911, 9920, 9930, 9931
MDS diagnosis	Medicare, ICD-9-CM Diagnosis	284.9, 285.0, 238.7 (prior to October 2006) 238.72, 238.73, 238.74, 238.75 (from October 2006 onwards)
Chemotherapy	Medicare, ICD-9-CM Diagnosis Medicare, ICD-9-CM Procedure Medicare, Revenue center codes Medicare, CPT Medicare, HCPCS	Medical evaluation: V58.1, V66.2, V67.2 Administration: 99.25 Administration: 0331, 0332, 0335 Administration: 96,400-96599 G0355-363, Q0083-5, Agents: J9000-9999; J0894, C9231, C9218, S0168
Allo-HCT	Medicare, ICD-9-CM Procedure Medicare, CPT Medicare, HCPCS	Administration: 41.02, 41.03, 4105, 41.06, 41.08 Administration: 38240 S2142
BM aspiration/biopsy:	Medicare, CPT	85097, 85095, 85102 (prior to January 2002) 38220, 38221, G0364 (from January 2002 onwards)
Flow cytometry	Medicare, CPT	88180 (prior to January 2005) 88184, 88185, 88187-88189 (after January 2005)
Cytogenetics	Medicare, CPT	3155F, 88237, 88261-88264, 88271-88275, 88280, 88283, 88285, 88289, 88291, 88299
HLA typing	Medicare, CPT	86812, 86813, 86816, 86817, 86821, 86822, 86825, 86826

SEER: Surveillance, Epidemiology, and End Results; PEDFS: Patient Entitlement and Diagnosis Summary File; ICD, World Health Organization International Classification for Disease; ICD-O-3: ICD for Oncology (3rd ed); ICD-9: ICD (9th rev); HCPCS: Healthcare Common Procedure Coding System; allo-HCT: allogeneic hematopoietic stem cell transplantation; MDS: myelodysplastic syndrome; CPT: current procedural terminology; BM: bone marrow; HLA: human leukocyte antigen.

Online Supplementary Table S2. WHO Classification of AML with ICD-O-3 codes.

ICD-O-3	WHO term	N (%)
	AMLs with recurrent cytogenetic translocations	
9896/3	AML with {t(8;21)(q22;q22)}, {AML1(CBF-alpha)/ETO}	47 (0.9)
9866/3	Acute promyelocytic leukemia {AML with t(15;17)(q22;q11-12) and variants, {PML/RAR-alpha}	156 (2.9)
9871/3	AML with abnormal bone marrow eosinophils {inv(16)(p13q22)} or {t(16;16)(p13;q11)}, {CBFb/MYH11}	22 (0.4)
9897/3	AML with 11q23 abnormalities {MLL}	29 (0.5)
9895/3	AML with multilineage dysplasia	396 (7.2)
9895/3	With prior myelodysplastic syndrome	
9895/3	Without prior myelodysplastic syndrome	
9920/3	AML and myelodysplastic syndromes, therapy-related	0
9920/3	Alkylating agent-related	
9920/3	Epipodophyllotoxin-related (some may be lymphoid)	
9920/3	Other types	
9861/3	AML not otherwise categorized	3309 (62)
9872/3	AML minimally differentiated	219 (4)
9873/3	AML without maturation	271 (5)
9874/3	AML with maturation	372 (6.8)
9867/3	Acute myelomonocytic leukemia	534 (9.7)
9891/3	Acute monocytic leukemia	0
9840/3	Acute erythroid leukemia	92 (1.7)
9910/3	Acute megakaryocytic leukemia	33 (0.6)
9870/3	Acute basophilic leukemia	0

Online Supplementary Table S3. Percentage of patients receiving diagnostic tests by age groups.

	Age groups (years)			
	65-69 (n=592) %	70-74 (n=970) %	75-79 (n=1088) %	≥80 (n=1984) %
BM aspiration/biopsy	81.7	75.8	73.3	64.2
Immunophenotype	67.3	63.2	58.1	54.2
Cytogenetics	44.0	39.1	35.9	29.5
HLA typing	16.2	11.0	5.5	3.2

BM: bone marrow; HLA: human leukocyte antigen.